{
    "hands_on_practices": [
        {
            "introduction": "Effective management of treatment-experienced HIV begins with the fundamental skill of quantifying drug resistance. Phenotypic assays provide a direct measure of how much more drug is needed to inhibit a patient's virus compared to a standard wild-type strain. This exercise focuses on calculating and interpreting the fold-change ($FC$) in the half-maximal inhibitory concentration ($IC_{50}$), a cornerstone metric in virology that determines whether a drug is likely to remain clinically active . Mastering this foundational concept is the first step toward making data-driven decisions in constructing a salvage regimen.",
            "id": "4910304",
            "problem": "A phenotypic susceptibility assay is performed for a treatment-experienced individual with Human Immunodeficiency Virus (HIV) infection. The assay reports a half-maximal inhibitory concentration ($IC_{50}$) for the reference wild-type isolate of $0.5$ ng/mL and an $IC_{50}$ for the patient’s recombinant isolate of $5$ ng/mL for a particular antiretroviral drug. A clinically validated fold-change cutoff of $4$ is used to classify whether the drug remains clinically active against the patient isolate when compared with wild-type.\n\nStarting only from core definitions relevant to phenotypic resistance testing in virology and pharmacology—namely, that $IC_{50}$ is the concentration at which the drug reduces viral replication to one-half of its baseline and that phenotypic susceptibility is commonly summarized by the fold-change in $IC_{50}$ of the patient isolate relative to wild-type—compute the fold-change and determine clinical activity by comparing it to the given cutoff.\n\nProvide your final answer as a row vector with two entries:\n- The first entry is the fold-change (unitless), rounded to three significant figures.\n- The second entry is a binary indicator of clinical activity, defined as $1$ if the drug is considered clinically active (fold-change less than or equal to the cutoff) and $0$ otherwise.\n\nExpress the fold-change as a pure number without units. The binary indicator must be exactly $1$ or $0$.",
            "solution": "We begin with the definitions. Let $IC_{50}$ denote the half-maximal inhibitory concentration. Let $IC_{50}^{\\mathrm{WT}}$ be the $IC_{50}$ for the wild-type reference isolate and $IC_{50}^{\\mathrm{P}}$ be the $IC_{50}$ for the patient isolate for the same drug and assay conditions. The phenotypic fold-change in susceptibility, denoted $F$, is defined by the ratio\n$$\nF \\equiv \\frac{IC_{50}^{\\mathrm{P}}}{IC_{50}^{\\mathrm{WT}}}.\n$$\nA clinically validated cutoff, denoted $C$, provides a decision rule for activity: if $F \\leq C$, the drug is considered clinically active against the patient isolate; if $F  C$, it is considered not clinically active due to reduced susceptibility.\n\nFrom the problem data, we have $IC_{50}^{\\mathrm{WT}} = 0.5$ ng/mL, $IC_{50}^{\\mathrm{P}} = 5$ ng/mL, and cutoff $C = 4$. Compute $F$:\n$$\nF = \\frac{IC_{50}^{\\mathrm{P}}}{IC_{50}^{\\mathrm{WT}}} = \\frac{5}{0.5} = 10.\n$$\nCompare $F$ to $C$:\n$$\n10  4 \\implies \\text{not clinically active}.\n$$\nDefine the activity indicator $A$ as\n$$\nA = \\begin{cases}\n1,  \\text{if } F \\leq C,\\\\\n0,  \\text{if } F  C.\n\\end{cases}\n$$\nThus, $A = 0$.\n\nThe fold-change should be rounded to three significant figures. Since $F = 10$ exactly, we report $10.0$ to reflect three significant figures.\n\nTherefore, the requested row vector is\n$$\n\\begin{pmatrix}\n10.0  0\n\\end{pmatrix}.\n$$",
            "answer": "$$\\boxed{\\begin{pmatrix}10.0  0\\end{pmatrix}}$$"
        },
        {
            "introduction": "After learning to quantify resistance, the next challenge is applying this knowledge to real-world regimen selection. This is particularly complex when considering regimen simplification for a virologically suppressed patient who has a history of prior resistance. This scenario introduces the critical concept of archived resistance—mutations that persist in the latent viral reservoir and can re-emerge if selective pressure is changed . This practice problem will challenge you to integrate your understanding of resistance mutations with the principles of combination therapy to avoid the peril of functional monotherapy, all while navigating potential drug-drug interactions and patient-centered goals.",
            "id": "4910257",
            "problem": "A $49$-year-old man with Human Immunodeficiency Virus type $1$ (HIV-$1$) infection has maintained virologic suppression (HIV RNA $50$ copies/mL) for $24$ months on dolutegravir plus tenofovir alafenamide/emtricitabine, taken as two pills once daily. He requests regimen simplification to reduce pill count and long-term toxicity. He has no history of virologic failure. A historical genotype from $2012$ showed the nucleoside reverse transcriptase mutation M184V during a brief period on lamivudine monotherapy years before establishing care; current proviral deoxyribonucleic acid (DNA) genotyping again detects archived M184V with no other nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or integrase strand transfer inhibitor (INSTI) resistance mutations. Hepatitis B surface antigen is negative, hepatitis B core antibody is negative, and hepatitis B deoxyribonucleic acid is undetectable. Estimated glomerular filtration rate is $75$ mL/min/$1.73$ m$^2$. Medications include omeprazole $20$ mg daily for gastroesophageal reflux disease and simvastatin $40$ mg daily for dyslipidemia; he has a history of statin-associated myalgia with high-intensity statins. He does not use recreational drugs or supplements. He denies plans for conception and is not pregnant.\n\nUsing the following core principles as your starting point: (i) antiretroviral therapy suppresses viral replication by combining at least two fully active agents to reduce the probability of resistance emergence given the high replication rate and mutation frequency of HIV-$1$, (ii) the M184V mutation confers high-level resistance to lamivudine and emtricitabine and reduces viral fitness while increasing susceptibility to tenofovir, and (iii) the genetic barrier to resistance differs among drug classes and agents (with dolutegravir and boosted darunavir having higher barriers than most), which of the following is the most appropriate management strategy to achieve the patient’s goals while minimizing the risk of functional monotherapy and drug–drug interactions?\n\nA. Switch to fixed-dose dolutegravir/lamivudine dual therapy now.\n\nB. Switch to fixed-dose dolutegravir/rilpivirine dual therapy after confirming no rilpivirine resistance.\n\nC. Switch to fixed-dose bictegravir/tenofovir alafenamide/emtricitabine single-tablet regimen.\n\nD. Switch to darunavir/cobicistat plus lamivudine dual therapy to avoid tenofovir exposure.\n\nSelect the single best option.",
            "solution": "The user-provided problem statement has been critically validated and is determined to be a valid clinical problem.\n\n**Problem Statement Analysis**\n\nThe problem describes a $49$-year-old male patient with Human Immunodeficiency Virus type $1$ (HIV-$1$) who is clinically stable and virologically suppressed on a two-pill, once-daily regimen of dolutegravir (DTG) plus a fixed-dose combination of tenofovir alafenamide/emtricitabine (TAF/FTC). The patient's objective is to simplify his regimen by reducing the pill count and minimizing long-term toxicity. The central clinical challenge is the presence of an archived M184V mutation, detected both historically and on a current proviral deoxyribonucleic acid (DNA) genotype. This mutation has critical implications for regimen selection, as articulated in the provided principles. Additionally, the patient's concomitant medications, omeprazole and simvastatin, must be considered for potential drug-drug interactions (DDIs). The patient has no evidence of Hepatitis B virus (HBV) infection, so the use of tenofovir or emtricitabine for HBV treatment is not required.\n\n**Core Principles Applied**\n\n1.  **Principle (i):** A successful antiretroviral therapy (ART) regimen requires at least two fully active drugs to prevent the emergence of drug resistance.\n2.  **Principle (ii):** The M184V mutation confers high-level resistance to lamivudine (3TC) and emtricitabine (FTC). This means 3TC and FTC are not fully active agents in this patient.\n3.  **Principle (iii):** Dolutegravir (DTG) and boosted darunavir (DRV) are agents with a high genetic barrier to resistance, making them robust components of an ART regimen.\n\n**Analysis of Management Options**\n\n**A. Switch to fixed-dose dolutegravir/lamivudine dual therapy now.**\n\n*   **Derivation:** This regimen consists of dolutegravir (DTG) and lamivudine (3TC). The patient has a documented M184V mutation. According to principle (ii), the M184V mutation confers high-level resistance to 3TC. Therefore, 3TC cannot be considered a fully active agent in this patient. Switching to DTG/3TC would violate principle (i), as it would constitute functional monotherapy with DTG. While DTG has a high barrier to resistance, using it as functional monotherapy in a patient with pre-existing nucleoside reverse transcriptase inhibitor (NRTI) resistance significantly increases the risk of virologic failure and the development of resistance to integrase strand transfer inhibitors (INSTIs). Pivotal clinical trials that established the efficacy of DTG/3TC (e.g., GEMINI $1$  $2$) explicitly excluded patients with known resistance to any component of the study regimen.\n*   **Verdict:** **Incorrect**. This option is contraindicated due to the high risk of treatment failure from functional monotherapy.\n\n**B. Switch to fixed-dose dolutegravir/rilpivirine dual therapy after confirming no rilpivirine resistance.**\n\n*   **Derivation:** This regimen consists of dolutegravir (DTG) and rilpivirine (RPV), available as a single-tablet regimen. This would meet the patient's goals of reducing pill count (from two to one) and avoiding tenofovir-related toxicity. The problem statement confirms no non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, which is a prerequisite for using RPV. However, the patient takes omeprazole $20$ mg daily, a proton-pump inhibitor (PPI). Rilpivirine absorption is highly pH-dependent and is significantly reduced in the presence of PPIs, which raise gastric pH. The co-administration of RPV and PPIs is pharmacokinetically contraindicated, as it can lead to subtherapeutic RPV levels, virologic failure, and the development of resistance to both DTG and RPV.\n*   **Verdict:** **Incorrect**. This option is contraindicated due to a severe and clinically significant drug-drug interaction between rilpivirine and omeprazole.\n\n**C. Switch to fixed-dose bictegravir/tenofovir alafenamide/emtricitabine single-tablet regimen.**\n\n*   **Derivation:** This regimen consists of bictegravir (BIC), tenofovir alafenamide (TAF), and emtricitabine (FTC), available as a single-tablet regimen (STR). This switch would achieve the patient's goal of reducing the pill count from two to one.\n    *   **Efficacy:** Bictegravir is a high-barrier INSTI, similar to DTG, and is fully active. Due to the M184V mutation, FTC is not a fully active agent. However, as stated in principle (ii), the M184V mutation increases viral susceptibility to tenofovir. Thus, TAF is not only active but hyper-active. The combination of a high-barrier INSTI (BIC) and an active NRTI (TAF) provides a robust regimen with two fully active components, consistent with principle (i). Maintaining the M184V-selected FTC also helps maintain the M184V mutation, which reduces viral fitness and enhances tenofovir activity. This is a standard and recommended approach for patients with isolated M184V.\n    *   **Toxicity  Interactions:** This option continues TAF, so it does not completely fulfill the goal of avoiding long-term tenofovir toxicity, although TAF is associated with less renal and bone toxicity than its predecessor, TDF. Bictegravir has a favorable drug-drug interaction profile and is not affected by omeprazole. It also does not have a clinically significant interaction with simvastatin that would require a change in management.\n*   **Verdict:** **Correct**. This option simplifies the regimen to a single pill, maintains potent virologic suppression in the presence of M184V, and avoids any contraindicating drug-drug interactions. It is the most appropriate and safest strategy among the choices.\n\n**D. Switch to darunavir/cobicistat plus lamivudine dual therapy to avoid tenofovir exposure.**\n\n*   **Derivation:** This regimen consists of a boosted protease inhibitor (darunavir/cobicistat or DRV/c) and lamivudine (3TC). It would remove tenofovir, addressing one aspect of the patient's toxicity concerns.\n    *   **Efficacy  Pill Burden:** As with option A, this regimen includes 3TC, to which the patient's virus is resistant due to the M184V mutation. This would be functional monotherapy with boosted darunavir, violating principle (i). Furthermore, this is a two-pill regimen (e.g., Symtuza® plus a 3TC tablet, or Prezcobix® plus a 3TC tablet), which does not reduce the pill count from the patient's current two-pill regimen. It fails the simplification goal.\n    *   **Drug Interactions:** This option introduces a severe drug-drug interaction. Cobicistat is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Simvastatin is extensively metabolized by CYP3A4. Their co-administration is contraindicated because cobicistat would dramatically increase simvastatin levels, elevating the risk of severe myopathy and rhabdomyolysis. This risk is particularly concerning in a patient with a prior history of statin-associated myalgia.\n*   **Verdict:** **Incorrect**. This option is inappropriate for three distinct reasons: it represents functional monotherapy, it involves a contraindicated and dangerous drug-drug interaction, and it fails to reduce the daily pill burden.",
            "answer": "$$\\boxed{C}$$"
        },
        {
            "introduction": "The goal of antiretroviral therapy is durable virologic suppression, but clinical practice is rarely straightforward. Clinicians often face ambiguous scenarios such as persistent low-level viremia, which occupies a grey zone between complete success and overt treatment failure. This final exercise challenges you to differentiate a transient \"virologic blip\" from evolving virologic failure, a critical distinction that determines the subsequent clinical pathway . Successfully navigating this problem requires synthesizing longitudinal monitoring data and applying a systematic approach to diagnosis and intervention, including deciding when and how to deploy resistance testing.",
            "id": "4910339",
            "problem": "A treatment-experienced adult with Human Immunodeficiency Virus type 1 (HIV-1) on a stable integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen has been virologically suppressed for the past year. Over a new 12-week interval of routine monitoring, plasma HIV-1 ribonucleic acid (RNA) values are measured at weeks 0, 4, 8, and 12 as 38, 320, 260, and 170 copies per milliliter, respectively. The patient reports no missed doses, although there has been a recent addition of other medications for comorbidities. There are no intercurrent acute infections reported. The assay used is a standard quantitative polymerase chain reaction (PCR)-based test with lower limit of detection of 20 copies per milliliter.\n\nUsing foundational clinical definitions and well-tested observations in HIV medicine—namely, that virologic suppression is typically defined as plasma HIV-1 RNA  50 copies per milliliter, that an isolated “virologic blip” is a single detectable value followed by return to suppression without a sustained pattern of viremia, that persistent viremia (on repeated measures) is associated with increased risk of resistance and may indicate evolving virologic failure when confirmed, and that genotypic and phenotypic resistance assays have minimum RNA thresholds for reliable amplification—classify the observed pattern as a virologic blip or indicative of evolving failure, and select the single best next diagnostic step.\n\nA. Classify as an isolated virologic blip; proceed with routine monitoring at $3$–$6$-month intervals without additional evaluation.\n\nB. Classify as persistent low-level viremia indicating evolving virologic failure; urgently assess adherence and drug–drug interactions and attempt plasma HIV-1 genotypic resistance testing while the patient remains on the current regimen; if genotyping is unsuccessful at low RNA levels, consider proviral deoxyribonucleic acid (DNA) genotyping; repeat HIV-1 RNA in $2$–$4$ weeks to confirm persistence.\n\nC. Classify as assay variability; repeat the same test in $12$ months without interim evaluation.\n\nD. Classify as acute intercurrent illness causing transient viremia; defer HIV-specific diagnostics and immediately switch ART empirically without resistance testing.\n\nE. Classify as persistent low-level viremia; obtain HIV-1 phenotypic resistance testing immediately, as it is accurate at $200$ copies per milliliter.",
            "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n**Step 1: Extract Givens**\n-   **Patient Profile:** Treatment-experienced adult with Human Immunodeficiency Virus type 1 (HIV-1).\n-   **Treatment:** On a stable integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen.\n-   **History:** Virologically suppressed for the past year.\n-   **Monitoring Data:** Plasma HIV-1 ribonucleic acid (RNA) values over a 12-week interval:\n    -   Week 0: 38 copies/mL\n    -   Week 4: 320 copies/mL\n    -   Week 8: 260 copies/mL\n    -   Week 12: 170 copies/mL\n-   **Patient Report:** No missed doses, but recent addition of other medications for comorbidities. No intercurrent acute infections.\n-   **Assay Details:** Standard quantitative polymerase chain reaction (PCR)-based test with a lower limit of detection of 20 copies/mL.\n-   **Provided Definitions:**\n    -   Virologic suppression: Plasma HIV-1 RNA  50 copies/mL.\n    -   Isolated \"virologic blip\": A single detectable value followed by a return to suppression.\n    -   Persistent viremia: Repeated measures of detectable virus, associated with increased risk of resistance and may indicate evolving virologic failure.\n    -   Resistance assays: Have minimum RNA thresholds for reliable amplification.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Groundedness:** The problem statement is scientifically sound. The scenario, including the patient profile, treatment type (INSTI-based ART), RNA values, and diagnostic considerations, represents a common and realistic clinical challenge in HIV medicine. The provided definitions for virologic suppression, blips, and persistent viremia are consistent with established clinical guidelines (e.g., those from the U.S. Department of Health and Human Services, DHHS).\n-   **Well-Posedness:** The problem is well-posed. It provides a discrete dataset and a set of definitions, asking for a classification and the best subsequent action. The information is sufficient to arrive at a single best answer based on standard clinical reasoning in HIV management.\n-   **Objectivity:** The problem is stated in objective, clinical language, free from subjective bias or opinion.\n\nThe problem statement does not violate any of the invalidity criteria. It is scientifically grounded, well-posed, objective, complete, and relevant.\n\n**Step 3: Verdict and Action**\nThe problem is valid. The solution will proceed with deriving the correct answer and evaluating each option.\n\n**Derivation of the Solution**\n\n1.  **Classification of the Virologic Pattern:**\n    The patient was previously suppressed (HIV-1 RNA  50 copies/mL). The current series of measurements is 38, 320, 260, and 170 copies/mL.\n    -   The value at week 0 (38 copies/mL) is below the clinical threshold for suppression (50 copies/mL), though it is detectable above the assay's limit (20 copies/mL).\n    -   The values at weeks 4, 8, and 12 are all > 50 copies/mL.\n    -   According to the provided definition, an \"isolated 'virologic blip' is a single detectable value followed by return to suppression.\" The current pattern shows three consecutive measurements above the suppression threshold over an 8-week period (from week 4 to 12). This is not a \"single\" value, and there has been no \"return to suppression.\" Therefore, this cannot be classified as an isolated blip.\n    -   The definition for \"persistent viremia\" is \"repeated measures\" of detectable virus. The sequence 320, 260, 170 copies/mL constitutes repeated measures of viremia above the suppression threshold. This pattern is best described as **persistent low-level viremia (LLV)**. Persistent LLV (typically defined as confirmed RNA levels between 50 and 1000 copies/mL) indicates that the ART regimen is not fully effective and is a risk factor for the selection of drug-resistance mutations and subsequent virologic failure. Therefore, the situation represents **evolving virologic failure**.\n\n2.  **Determination of the Next Diagnostic Step:**\n    Given the classification of persistent LLV/evolving virologic failure, the clinical objectives are to identify the cause and gather information to guide future treatment.\n    -   **Investigate Causes:** The most common causes of virologic failure in a previously stable patient are suboptimal adherence and drug-drug interactions (DDIs). The problem states the patient reports no missed doses but has started new medications. This makes the investigation of DDIs a high priority. Certain INSTIs are susceptible to interactions, for example, with polyvalent cations found in antacids and supplements, which can chelate the drug and reduce its absorption. A thorough review of all medications is essential. Adherence should also be reassessed in detail.\n    -   **Confirm and Trend Viremia:** Before making major changes, it is standard practice to confirm that viremia is indeed persistent. Repeating the HIV-1 RNA test in a short interval (e.g., 2–4 weeks) is indicated.\n    -   **Assess for Drug Resistance:** It is critical to determine if the virus has developed resistance to the current regimen. The standard test for this is **plasma HIV-1 genotypic resistance testing**. This test should be performed while the patient is still taking the failing regimen to ensure that the resistant viral variants are under selective pressure and thus more likely to be detected. However, as noted in the problem, these assays have minimum viral load requirements, typically 200-500 copies/mL. With recent values of 320 and 260 copies/mL, the test might be successful, but at 170 copies/mL, it might fail. Therefore, it is appropriate to \"attempt\" it.\n    -   **Contingency for Low Viral Load:** If the plasma RNA level is too low for standard genotyping, **proviral DNA genotyping** is an alternative. This method analyzes the viral DNA integrated into the host's cells and can detect resistance mutations even when plasma viremia is low or undetectable.\n\nCombining these steps, the optimal management strategy is to classify the condition as persistent LLV indicating evolving failure, investigate adherence and DDIs, repeat the RNA measurement in 2–4 weeks to confirm persistence, and attempt plasma genotype testing, with a plan to use proviral DNA genotyping if needed.\n\n**Option-by-Option Analysis**\n\n**A. Classify as an isolated virologic blip; proceed with routine monitoring at $3$–$6$-month intervals without additional evaluation.**\n-   This option incorrectly classifies the virologic pattern. The data shows three consecutive viral load measurements > 50 copies/mL, which is by definition persistent and not an isolated blip. The proposed action of infrequent monitoring without further workup is clinically inappropriate and risks progression to high-level failure with extensive drug resistance.\n-   **Verdict:** Incorrect.\n\n**B. Classify as persistent low-level viremia indicating evolving virologic failure; urgently assess adherence and drug–drug interactions and attempt plasma HIV-1 genotypic resistance testing while the patient remains on the current regimen; if genotyping is unsuccessful at low RNA levels, consider proviral deoxyribonucleic acid (DNA) genotyping; repeat HIV-1 RNA in $2$–$4$ weeks to confirm persistence.**\n-   This option correctly classifies the pattern as persistent low-level viremia suggesting evolving virologic failure. It outlines a comprehensive and correct management plan that aligns perfectly with current clinical guidelines: investigate reversible causes (adherence, DDIs), attempt the standard-of-care resistance test (genotype) while acknowledging its limitations, propose the correct alternative (proviral DNA genotype), and include confirmatory RNA testing.\n-   **Verdict:** Correct.\n\n**C. Classify as assay variability; repeat the same test in $12$ months without interim evaluation.**\n-   This option incorrectly attributes a sustained, significant rise in viral load to mere assay variability. While PCR assays have inherent variability, a pattern of consistently detectable viremia well above the suppression threshold reflects a true biological phenomenon. The proposed action of waiting 12 months is dangerous and deviates significantly from the standard of care.\n-   **Verdict:** Incorrect.\n\n**D. Classify as acute intercurrent illness causing transient viremia; defer HIV-specific diagnostics and immediately switch ART empirically without resistance testing.**\n-   This option makes an assumption (\"acute intercurrent illness\") that is explicitly contradicted by the problem statement (\"There are no intercurrent acute infections reported\"). Furthermore, switching ART empirically without resistance data is a major clinical error, as it may lead to the selection of a new regimen to which the virus is also resistant.\n-   **Verdict:** Incorrect.\n\n**E. Classify as persistent low-level viremia; obtain HIV-1 phenotypic resistance testing immediately, as it is accurate at $200$ copies per milliliter.**\n-   While the classification is correct, the proposed action is flawed. First, genotypic testing, not phenotypic testing, is the standard initial resistance assay for treatment failure. Second, the claim that phenotypic testing is accurate at  200 copies/mL is factually incorrect for standard commercial platforms, which typically have viral load requirements similar to or higher than those for genotyping.\n-   **Verdict:** Incorrect.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}